EFFICACY AND SAFETY OF COMBINED PHOSPHODIESTERASE TYPE 5 INHIBITORS AS A SALVAGE MEDICAL TREATMENT IN PATIENTS WITH ERECTILE DYSFUNCTION AFTER NERVE-SPARING RADICAL PROSTATECTOMY
1Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
2Joint Institute for Regenerative Medicine, Kyungpook National University, Daegu, Republic of Korea
DOI: 10.31083/jomh.v16i3.288 Vol.16,Issue 3,July 2020 pp.138-146
Published: 16 July 2020
Penile rehabilitation therapy using phosphodiesterase type 5 inhibitors (PDE5i) is used widely as a first-line therapy in patients with erectile dysfunction (ED) after radical prostatectomy (RP). However, many patients undergoing such therapy still complain of inappropriate erectile function (EF). Therefore, we evaluated the efficacy and safety of combined PDE5i therapy as a salvage medical treatment in patients nonresponsive to initial penile rehabilitation using daily PDE5i after nerve-sparing RP.
We retrospectively reviewed 58 nonresponders (Erection Hardness Score [EHS] of 2 or less) to penile rehabilitation using tadalafil (5 mg) daily for more than 12 weeks and who subsequently received combined PDE5i therapy (tadalafil [5 mg] once daily with sildenafil [50 mg] or udenafil [100 mg] on demand). Success after combined therapy is defined by EHS scores of 3 or 4. Safety was assessed by observing drug tolera-bility and adverse events.
Of the 58 patients, combined therapy was successful in 39.7% of cases. The mean preoperative International Index of Erectile Function (IIEF-5) score was significantly higher in the success group after combined PDE5i therapy compared with the failure group (success group, 15.9 ± 5.1 versus failure group, 12.3 ± 5.6; p = 0.018). According to ED classification based on preoperative IIEF-5 scores, the success rates of no/mild/mild-to-moderate ED group and moderate/severe ED group were 50.0% (18/36) and 22.7% (5/22), respec-tively (p = 0.039). The success and failure groups did not differ significantly in any other characteristic. The drugs were tolerated well by all patients and no serious adverse events were observed.
Combined PDE5i therapy improves EF in patients nonresponsive to standard penile rehabilitation using daily PDE5i after nerve-sparing RP, especially for patients without preoperative moderate or severe ED. In such patients, combined PDE5i therapy could be considered before invasive therapies.
erectile dysfunction; phosphodiesterase 5 inhibitors; prostate cancer; prostatectomy; treatment outcome
Jun Nyung Lee,Jae-Wook Chung,Soon Oh Kwon,Kyeong-Hyeon Byeon,Dong Jin Park,Seock Hwan Choi,Bum Soo Kim,Hyun Tae Kim,Tae-Hwan Kim,Eun Sang Yoo,Yun-Sok Ha,Tae Gyun Kwon. EFFICACY AND SAFETY OF COMBINED PHOSPHODIESTERASE TYPE 5 INHIBITORS AS A SALVAGE MEDICAL TREATMENT IN PATIENTS WITH ERECTILE DYSFUNCTION AFTER NERVE-SPARING RADICAL PROSTATECTOMY. Journal of Men's Health. 2020. 16(3);138-146.
1. Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatec-tomy: A meta-analysis. J Sex Med 2009;6(9):2538–
2. Kim JH, Lee SW. Current status of penile reha-bilitation after radical prostatectomy. Korean J Urol 2015;56(2):99–108. https://doi.org/10.4111/kju.2015.56.2.99
3. Fode M, Ohl DA, Ralph D, Sønksen J. Penile reha-bilitation after radical prostatectomy: What the evi-dence really says. BJU Int 2013;112(7):998–1008. https://doi.org/10.1111/bju.12228
4. Nelson CJ, Scardino PT, Eastham JA, Mulhall JP. Back to baseline: Erectile function recovery after radical prostatectomy from the patients’ perspec-tive. J Sex Med 2013;10(6):1636–43. https://doi. org/10.1111/jsm.12135
5. Liu C, Lopez DS, Chen M, et al. Penile Rehabilitation Therapy Following Radical Prostatectomy: A Meta-Analysis. J Sex Med 2017;14(12):1496-1503. http://doi.org/10.1016/
6. Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: Recovery and preserva-tion of erectile function, sexual desire, and orgas-mic function. Eur Urol 2012;62(2):273–86. https://doi.org/10.1016/j.eururo.2012.04.047
7. Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions part 1: Choosing the right patient at the right time for the right surgery. Eur Urol 2012;62(2):261–72. https://doi.org/10.1016/j. eururo.2012.04.046
8. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: Practice patterns among the international society for sexual medicine practi-tioners. J Sex Med 2009;6(7):2032–8. https://doi. org/10.1111/j.1743-6109.2009.01269.x
9. Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Ratel HR, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: A ran-domised placebo-controlled study (REACTT). Eur Urol 2014;65(3):587–96. https://doi.org/10.1016/j. eururo.2013.09.051
10. Sridhar AN, Cathcart PJ, Yap T, Hines J, Nathan S, Briggs TP, et al. Recovery of baseline erectile func-tion in men following radical prostatectomy for high-risk prostate cancer: A prospective analysis using validated measures. J Sex Med 2016;13(3):435–43. https://doi.org/10.1016/j.jsxm.2016.01.005
11. Polito M, d’Anzeo G, Conti A, Muzzonigro G. Erectile rehabilitation with intracavernous alprosta-dil after radical prostatectomy: Refusal and dropout rates. BJU Int 2012;110(11 Pt C):E954–7. https://doi. org/10.1111/j.1464-410X.2012.11484.x
12. Hellstrom WJ, Montague DK, Moncada I, Carson C, Minhas S, Faria G, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunc-tion. J Sex Med 2010;7(1 Pt 2):501–23. https://doi. org/10.1111/j.1743-6109.2009.01626.x
13. Cui H, Liu B, Song Z, Fang J, Deng Y, Zhang S, et al. Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia 2015;47(1):20–4. https://doi.org/10.1111/and.12216
14. Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K. Validation of the erec-tion hardness score. J Sex Med 2007;4(6):1626–34. https://doi.org/10.1111/j.1743-6109.2007.00600.x
15. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11(6):319–
16. Chen RC, Clark JA, Manola J, Talcott JA. Treatment “mismatch” in early prostate cancer –Do treatment choices take patient quality of life into account? Cancer 2008;112(1):61–8. https://doi.org/10.1002/cncr.23138
17. Chung E, Brock G. Sexual rehabilitation and can-cer survivorship: A state of art review of current literature and management strategies in male sex-ual dysfunction among prostate cancer survivors. J Sex Med 2013;10(Suppl 1):102–11. https://doi. org/10.1111/j.1743-6109.2012.03005.x
18. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306(11):1205–14. https://doi. org/10.1001/jama.2011.1333
19. Rabbani F, Schiff J, Piecuch M, Yunis LH, Eastham JA, Scardino PT, et al. Time course of recovery of erectile function after radical retro-pubic prostatectomy: Does anyone recover after 2 years? J Sex Med 2010;7(12):3984–90. https://doi. org/10.1111/j.1743-6109.2010.01969.x
20. Mulhall JP, Bella AJ, Briganti A, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010;7(4):1687–
21. Wang X, Wang X, Liu T, He Q, Wang Y, Zhang X. Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. PLoS One 2014;9(3):e91327. https://doi.org/10.1371/journal.pone.0091327
22. Arslan D, Esen AA, Secil M, Aslan G, Celebi I, Dicle O. A new method for the evaluation of erectile dysfunction: Sildenafil plus Doppler ultra-sonography. J Urol 2001;166(1):181–4. https://doi. org/10.1016/S0022-5347(05)66105-8
23. Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metabo Clin North Am 2007;36(2):465–79. https://doi.org/10.1016/j. ecl.2007.02.001
24. Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tada-lafil. J Sex Med 2009;6(7):2039–48. https://doi. org/10.1111/j.1743-6109.2009.01301.x
25. Rosanoa GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardio-vascular risk. Eur Urol 2005;47(2):214–22. https://doi.org/10.1016/j.eururo.2004.10.002
26. Althof SE, Rubio-Aurioles E, Kingsberg S, Zeigler H, Wong DG, Burns P. Impact of tadalafil once daily in men with erectile dysfunction-including a report of the partners’ evaluation. Urology 2010;75(6):1358-
63. http://doi: 10.1016/j.urology.2009.11.066.
27. Michl U, Molfenter F, Graefen M, Tennstedt P, Ahyai S, Beyer B, et al. Use of phosphodiester-ase type 5 inhibitors may adversely impact bio-chemical recurrence after radical prostatectomy. J Urology 2015;193(2):479–83. https://doi.org/10.1016/j. juro.2014.08.111
28. Kim SJ, Kim JH, Chang HK, Kim KH. Let’s rethink-ing about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy. J Exerc Rehabil 2016;12(3):143–
29. He Q, Liao BH, Xiao KW, Zhou L, Feng SJ, Li H, et al. Is there a relationship between phosphodies-terase type 5 inhibitors and biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis. Int Urol Nephrol 2018;50(12):2113–
30. Jo JK, Kim K, Lee SE, Lee JK, Byun S-S, Hong SK. Phosphodiesterase type 5 inhibitor use follow-ing radical prostatectomy is not associated with an increased risk of biochemical recurrence. Ann Surg Oncol 2016;23(5):1760–7. https://doi.org/10.1245/s10434-015-5059-1
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)
Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.
Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).